| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
We analyzed Calreticulin (CALR), which is frequently mutated in essential thrombocythemia and primary myelofibrosis. The role of CALR in normal hematopoiesis and the mechanism by which mutant CALR causes MPN were elucidated in in vitro experiments and in in vivo experiments by creating multiple mouse models. We found that CALR mutation conferred cell proliferation and cytokine independence and caused mice to develop essential thrombocythemia. However, at the same time, it also became clear that they have a negative effect on hematopoietic stem cells, suggesting that maintenance of mutated hematopoietic stem cells and development of disease require elements other than CALR mutation.
|
